PMID- 31022997
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220409
IS  - 2005-3606 (Print)
IS  - 2005-5447 (Electronic)
IS  - 2005-3606 (Linking)
VI  - 12
IP  - 2
DP  - 2019 Jul 31
TI  - Efficacies of Stem Cell Therapies for Functional Improvement of the beta Cell in 
      Patients with Diabetes: A Systematic Review of Controlled Clinical Trials.
PG  - 195-205
LID - 10.15283/ijsc18076 [doi]
AB  - BACKGROUND AND OBJECTIVES: This study was performed to investigate whether stem 
      cell therapy enhances beta cell function by meta-analysis with proper consideration 
      of variability of outcome measurements in controlled trial of type 1 diabetes 
      mellitus (T1DM) and type 2 diabetes mellitus (T2DM) patients. METHODS: A 
      systematic search was performed from inception to January 2018 in PubMed, EMBASE, 
      and Cochrane databases. beta cell function was assessed by stimulated C-peptide, 
      fasting C-peptide, normal glycosylated hemoglobin levels (HbA1C), and exogenous 
      insulin dose patterns. The quality of the studies were assessed by both the 
      Cochrane Collaboration's Risk of Bias (ROB) for Randomized controlled trials and 
      the Risk of Bias in Non-randomized Studies of Interventions (ROBINS-I) for 
      non-randomized controlled trials. RESULTS: From the selected final 15 articles, 
      total of 16 trials were analyzed. There were 6 T1DM trials (total 153 cases) and 
      10 T2DM trials (total 457 cases). In T2DM patients, the changes in stimulated 
      C-peptide, HbA1c, and exogenous insulin dose versus baseline showed a favorable 
      pattern with a significant heterogeneity in stem cell therapy. In T1DM, there was 
      no significant difference between control group and stem cell therapy group in 
      three indicators except for HbA1c. Most of the studies were rated as having high 
      risk of bias in the quality assessment. CONCLUSIONS: The stem cell therapy for DM 
      patients is not effective in T1DM but seems to be effective in improving the beta 
      cell function in T2DM. However the observed effect should be interpreted with 
      caution due to the significant heterogeneity and high risk of bias within the 
      studies. Further verification through a rigorously designed study is warranted.
FAU - Hwang, Gyudeok
AU  - Hwang G
AD  - The Catholic University of Korea, Catholic Medical Center, Seoul, Korea.
FAU - Jeong, Hyunsuk
AU  - Jeong H
AD  - Department of Preventive Medicine, College of Medicine, The Catholic University 
      of Korea, Seoul, Korea.
FAU - Yang, Hae Kyung
AU  - Yang HK
AD  - Cell and Gene Therapy Products Division, National Institute of Food and Drug 
      Safety Evaluation, Ministry of Food and Drug Safety, Cheongju, Korea.
FAU - Kim, Hun-Sung
AU  - Kim HS
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul 
      St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 
      Seoul, Korea.
FAU - Hong, Hanter
AU  - Hong H
AD  - The Catholic University of Korea, Catholic Medical Center, Seoul, Korea.
FAU - Kim, Na Jin
AU  - Kim NJ
AD  - Medical Library, The Catholic University of Korea, Seoul, Korea.
FAU - Oh, Il-Hoan
AU  - Oh IH
AD  - Catholic High-Performance Cell Therapy Center & Department of Medical Life 
      Science, College of Medicine, The Catholic University of Korea, Seoul, Korea.
FAU - Yim, Hyeon Woo
AU  - Yim HW
AD  - Department of Preventive Medicine, College of Medicine, The Catholic University 
      of Korea, Seoul, Korea.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Korea (South)
TA  - Int J Stem Cells
JT  - International journal of stem cells
JID - 101497587
PMC - PMC6657948
OTO - NOTNLM
OT  - C-peptide
OT  - Diabetes mellitus
OT  - Stem cell
OT  - beta cell
COIS- Potential Conflict of Interest The authors have no conflicting financial 
      interest.
EDAT- 2019/04/27 06:00
MHDA- 2019/04/27 06:01
PMCR- 2019/04/30
CRDT- 2019/04/27 06:00
PHST- 2018/09/04 00:00 [received]
PHST- 2019/01/02 00:00 [revised]
PHST- 2019/02/11 00:00 [accepted]
PHST- 2019/04/27 06:00 [pubmed]
PHST- 2019/04/27 06:01 [medline]
PHST- 2019/04/27 06:00 [entrez]
PHST- 2019/04/30 00:00 [pmc-release]
AID - ijsc18076 [pii]
AID - ijsc-12-195 [pii]
AID - 10.15283/ijsc18076 [doi]
PST - ppublish
SO  - Int J Stem Cells. 2019 Jul 31;12(2):195-205. doi: 10.15283/ijsc18076.